Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 20

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 20
---
 in Assaf Harofeh Medical Center. On April of 2017 until April of 2021, he served as a professor at Assaf Harofeh Medical Center. He began his medical career in August of 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May of 2017. Professor Revel received his PhD from Tel -AvivUniversity, and an M.D degree from the Hebrew University of Jerusalem. Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program):Dr. Eric Konofal was appointed as our Interim Chief Scientific Officer in February 2021. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 27 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal serves as a senior medical consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his medical doctorate and Ph.D. from the University Pierre -MarieCurie, Paris/France. Proposal:The Board of Directors proposes that the following persons shall be elected, on an advisory basis, as members of the senior management on an advisory basis: Mr.Ronen Twito (Executive Chairman and Chief Executive Officer) Prof. Michel Revel, MD, PhD (Chief Scientific Officer) Mr.Kfir Molakandov, PhD (Vice President Research and Development) Mr.Ariel Revel, MD (Director of Medical Affairs) 11.Compensation for the Members of the Board of Directors and Executive Management 11.1 Approval of Compensation for the Board of Directors Explanation:In connection with the Merger and the renewal of the Board of Directors, the Company is proposing that the previously approved compensation for the Board of Directors is adjusted. The Board of Directors believes that the newly proposed compensation for the Board of Directors adequately reflects their responsibility and expected work load. respective efforts on behalf of the Company. Proposal:The Board of Directors proposes (i) to approve a new maximum aggregate amount of CHF [•] (cash base compensation including all applicable social security contributions) for the fixed compensation of the Board of Directors; (ii) to approve the grant of equity or equity -linkedinstruments with maximum aggregate amount of CHF [•](equity or